| Gene symbol | S | Synonyms | E2 | Type of gene | protein-coding |
| Chromosome | - | Map location | NC_004718.3 (21492..25259) | dbXrefs | |
| Gene perturbation-related omics dataset | PerturbAtlas | ||||
| Description | spike glycoprotein | ||||
| GTO ID | GTC2653 |
| Trial ID | NCT04838847 |
| Disease | COVID-19 | Coronavirus Infectious Disease | Severe Acute Respiratory Syndrome |
| Altered gene | S |
| Therapeutic/Target gene | Therapeutic gene |
| Therapy | mRNA vaccine |
| Treatment | CVnCoV|CV07050101 |
| Phase | Phase3 |
| Recruitment status | Withdrawn |
| Title | COVID-19 (CoviCompareCV): A Phase 3, Non-randomized, Open Label Clinical Trial to Evaluate the Immunogenicity and Safety of the Investigational SARS-CoV-2 mRNA Vaccine CVnCoV Administered Intramuscularly in Adults Aged 65 Years or Above Compared to Younger Adults Aged 18-45 Years |
| Year | 2021 |
| Country | Germany |
| Company sponsor | CureVac |
| Other ID(s) | CV-NCOV-012|2020-005064-54 |
| Vector information | |||
|
|||
| Cohort1: Aged ≥65 Years | |||||||||
|
|||||||||
| Cohort2: Aged 18-45 Years | |||||||||
|
|||||||||